Under the agreement, Cellares will use its Cell Shuttle and Cell Q systems to automate TSC-101 manufacturing processes.
Cellares will automate the TSC-101 manufacturing and testing processes on the Cell Shuttle and the Cell Q automated testing system.
Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...
Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study Healthy volunteers were recruited and underwent ...
Collaboration will apply Cellares' fully automated Cell Shuttle® and Cell Q™ platforms to TScan’s lead TCR-T therapy candidate TSC-101 as a potentially scalable and cost-efficient path to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results